Categories: News

EssilorLuxottica: Disclosure of transactions in own shares

Disclosure of transactions in own shares

Paris, France (April 29, 2025 – 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2024, EssilorLuxottica declares that from April 22, 2025, to April 28, 2025, inclusive, the following share buybacks were carried out:

Name of the issuer Identity code of the Issuer Day of the transaction Identity code of the financial
instrument		 Total daily volume (in
number of shares)		 Daily weighted average
purchase price of the shares (€) *		 Market (MIC Code)
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 22/04/2025 FR0000121667 58,184 248.4041 XPAR
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 22/04/2025 FR0000121667 13,718 248.6304 CEUX
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 24/04/2025 FR0000121667 18,929 249.5152 XPAR
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 24/04/2025 FR0000121667 2,474 249.6460 CEUX
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 24/04/2025 FR0000121667 338 249.5929 TQEX
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 24/04/2025 FR0000121667 481 249.6158 AQEU
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 28/04/2025 FR0000121667 30,778 249.9356 XPAR
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 28/04/2025 FR0000121667 15,983 249.9974 CEUX
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 28/04/2025 FR0000121667 5,000 249.9855 TQEX
ESSILORLUXOTTICA 549300M3VH1A3ER1TB49 28/04/2025 FR0000121667 5,000 249.9807 AQEU
  TOTAL 150,885 249.1768  

* Rounded to four decimal places

Attachment

Staff

Share
Published by
Staff
7 months ago

Recent Posts

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…

5 hours ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…

5 hours ago

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…

5 hours ago

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…

5 hours ago

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

5 hours ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

5 hours ago